The half yearly appendix 4D gives lots of detail as to where the D&A charges comes from. All the info is on pages 13,17 and 18. Page 23 also says that the assets aquired fro the track acquisition were 18.6M. This can be reconcilled to the details on P 18.
The acccounts say that they spent 80K on plant and equipment for the half and that is the total capital spend.
In my view NPAT is a very poor measure for this company as they have D&A cahrges of around 4.5M a year with next to none new apital spends
As an example EBITDA was 3.25M
Annualise 13M
Less Interest 2.9M (if no repayments or re-negotiation)
Less D & A 4.5
Tax 25% 1.4
NPAT 4.2
Free Cash flow however is 8.7
These numbers are very conservative the EBITDA grows qtr on qtr.
So with a EV of around 56M I would undervalued using cash flow but does not look that attractive based on NPAT
And as they pay off the debt the EV gets lower and the financial metrics much more attractive
- Forums
- ASX - By Stock
- UNT
- Record cash receipts for 4th quarter
Record cash receipts for 4th quarter, page-195
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $15.97M |
Open | High | Low | Value | Volume |
1.3¢ | 1.3¢ | 1.3¢ | $3.906K | 300.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 5651798 | 1.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.4¢ | 918236 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 5651798 | 0.013 |
14 | 3328379 | 0.012 |
2 | 632304 | 0.011 |
6 | 1488966 | 0.010 |
2 | 1100000 | 0.009 |
Price($) | Vol. | No. |
---|---|---|
0.014 | 918236 | 5 |
0.015 | 849000 | 4 |
0.016 | 240962 | 4 |
0.017 | 766142 | 4 |
0.018 | 1108178 | 3 |
Last trade - 10.53am 12/11/2024 (20 minute delay) ? |
Featured News
UNT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online